NCT01025999

Brief Summary

This study is designed as a prospective clinical trial aimed at investigating the mechanisms behind observed improvements in type 2 diabetes mellitus (T2DM) following bariatric surgery. The majority of patients with T2DM who are undergoing Roux-en-Y gastric bypass (RYGB) surgery, in particular, experience complete remission of T2DM almost immediately post-surgery. This response occurs before significant weight loss is possible. To assess the mechanisms involved with disease resolution, the investigators propose a study to evaluate patients at the UW Medical Center (UWMC) who have T2DM and are undergoing RYGB with G (gastronomy)-tube placement as part of their clinical care. The investigators are interested in this sub-population as the G-tube allows us the unique opportunity to evaluate glycemic control and insulin response following delivery or exclusion of nutrients to the otherwise bypassed portion of the gastrointestinal tract. The investigators hypothesize that nutrient delivery to the proximal GI tract will reverse RYGB-mediated improvements in glucose homeostasis, possibly in association with changes in nutrient-regulated gut peptides involved in glucose control.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
7

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jan 2010

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 2, 2009

Completed
2 days until next milestone

First Posted

Study publicly available on registry

December 4, 2009

Completed
28 days until next milestone

Study Start

First participant enrolled

January 1, 2010

Completed
5.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2015

Completed
Last Updated

March 31, 2016

Status Verified

March 1, 2016

Enrollment Period

5.4 years

First QC Date

December 2, 2009

Last Update Submit

March 29, 2016

Conditions

Keywords

RYGBGastrostomy tubeDMGastric Bypass

Outcome Measures

Primary Outcomes (1)

  • Determine if the improvements in glycemic control occurring early after RYGB can be reversibly inactivated and activated through delivery or exclusion of nutrients in the bypassed proximal small intestine.

    1/2010 - 6/2014

Secondary Outcomes (1)

  • To evaluate whether improvements in glucose control occurring early after RYGB are related to altered insulin secretion, insulin sensitivity, or both.

    1/2010-6/2014

Study Arms (1)

RYGB

UWMC patients undergoing RYGB surgery with routine placement of Gastrostomy tube.

Other: No intervention

Interventions

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients planning to undergo RYGB at UWMC with planned placement of gastrostomy tube.

You may qualify if:

  • Age 18 years or greater and planning to undergo RYGB at UWMC
  • Ability to speak English and communicate effectively with research staff
  • Ability to return for follow-up visits at UWMC
  • Adequate IV access
  • A G-tube is planned as part of the bariatric surgical procedure
  • Documented T2DM (fasting plasma glucose \>125 mg/dL) that is treated with lifestyle efforts or by taking acceptable oral medications

You may not qualify if:

  • Informed consent not obtained
  • Unlikely to comply with the protocol
  • Current HbA1c \>8.5% or fasting blood glucose \>180 mg/dL
  • Serum creatinine \>1.7 mg/dL
  • Use of unacceptable diabetes medications at baseline

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Washington Medical Center

Seattle, Washington, 98195, United States

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Plasma collected to measure markers of metabolic activity.

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Study Officials

  • David R Flum, MD, MPH

    University of Washington

    PRINCIPAL INVESTIGATOR
  • David E Cummings, MD

    University of Washington

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

December 2, 2009

First Posted

December 4, 2009

Study Start

January 1, 2010

Primary Completion

June 1, 2015

Study Completion

June 1, 2015

Last Updated

March 31, 2016

Record last verified: 2016-03

Locations